ACIU News and Press, AC Immune SA From 03/14/24

2024-03-14 16:55:37 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts Roche ends AC Immune partnership for Alzheimer’s drugs AC Immune issues updates on Phase 2 studies, cash runway Read the full article on Seekin...

2024-03-14 07:12:31 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts Roche ends AC Immune partnership for Alzheimer’s drugs AC Immune issues updates on Phase 2 studies, cash runway Seeking Alpha’s Quant Rati...

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2 ACI-24.060 for Alzheim...

2024-01-22 08:52:21 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune issues updates on Phase 2 studies, cash runway AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating o...

AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the optimal approach for precision prevention of neurodegenerative di...

2024-01-03 09:23:46 ET More on AC Immune AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts AC Immune Alzheimer's drug advanced into Phase 2b testing Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune ...

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and is expected to complete cohort 3 in January; 6-month and 12-month amyloid PET data expecte...

2023-12-18 18:25:18 ET Summary Additional interim immunogenicity data using ACI-24.060 from the phase 1b/2 study, targeting Alzheimer's Disease patients, expected before end of 2023. 6-month amyloid plaque reduction data, from phase 1b/2 study targeting AD patients using ACI-24.06...

2023-12-15 13:48:22 ET More on AC Immune Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune For further details see: AC Immune Alzheimer's drug advanced into Phase 2b testing

2023-12-15 08:26:35 ET More on AC Immune Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune For further details see: AC Immune prices its 14.3M shares offering